Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -2.91% 8.35 8.20 8.50 8.45 8.35 8.45 531,583 14:09:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.6 -1.0 - 13

N4 Pharma PLC Notice of AGM & Posting Annual Report and Accounts

25/02/2021 7:00am

UK Regulatory (RNS & others)

N4 Pharma (LSE:N4P)
Historical Stock Chart

From Jan 2021 to Jul 2021

Click Here for more N4 Pharma Charts.


RNS Number : 2412Q

N4 Pharma PLC

25 February 2021

25 February 2021

N4 Pharma plc

("N4 Pharma" or the "Company")

Notice of Annual General Meeting


Posting of Annual Report and Accounts

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, announces that the Company's audited accounts for the year ended 31 December 2020, together with the notice of Annual General Meeting ("AGM"), are now available on the Company's website and will be posted to shareholders today.

The AGM will be held at 10.00am on 24 March 2021. In line with current Covid-19 restrictions and in line with the Company's Articles of Association, this year's AGM will be a virtual meeting, full details of which are contained in the notice convening the AGM.


 N4 Pharma plc 
 Nigel Theobald, CEO                            Via IFC Advisory 
 Luke Cairns, Executive Director 
 SP Angel Corporate Finance LLP                 Tel: +44(0)20 3470 
 Nominated Adviser and Joint Broker 
 Matthew Johnson/Caroline Rowe (Corporate 
 Vadim Alexandre/Rob Rees (Corporate Broking) 
 Turner Pope Investments (TPI) Limited          Tel: +44(0)20 3657 
 Joint Broker 
 Andy Thacker/Zoe Alexander 
 IFC Advisory Ltd                               Tel: +44(0)20 3934 
  Financial PR                                   6630 
  Graham Herring 
  Zach Cohen 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

February 25, 2021 02:00 ET (07:00 GMT)

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart
ADVFN Advertorial
Your Recent History
N4 Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210724 11:23:30